Pfizer Fellowship Grant Request for Proposals: Transthyretin Cardiac Amyloidosis Fellowship
Pfizer funds a competitive fellowship for German institutions to train physicians in the diagnosis, treatment, and monitoring of transthyretin cardiac amyloidosis over six months.
Funder: Pfizer Inc.
Due Dates: July 15, 2026
Funding Amounts: Up to €50,000 for one fellow; project duration up to 6 months
Summary: Competitive fellowship grant for German institutions to train physicians in transthyretin cardiac amyloidosis diagnosis, treatment, and monitoring.
Key Information: Applications submitted after the deadline will not be reviewed; funding is institution-based, not individual.
Description
This competitive fellowship grant, funded by Pfizer Inc., is designed to advance the clinical and research training of healthcare professionals in transthyretin cardiac amyloidosis (ATTR-CM) within Germany. The program supports institutions with established experience in managing ATTR-CM patients, enabling them to mentor and educate a fellow physician over a 6-month period. The goal is to strengthen expertise in the recognition, diagnosis, treatment, and monitoring of ATTR-CM, thereby enhancing standards of care and patient outcomes through structured, interdisciplinary education and knowledge transfer.
